Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Elanco Animal Health Inc

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing fac.

Merck Animal Health to Acquire Elanco's Aqua Business

Transaction reinforces Elanco's commitment to most significant value creation opportunities in pet health and livestock sustainability Enables company to accelerate debt paydown by $1.05B to $1.1B GREENFIELD, Ind. , Feb. 5, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement to sell its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, which represents approximately 7.4x the estimated 2023 revenue of the Elanco aqua business.

Elanco Announces Sale of Aqua Business for $1.3 Billion

BioNTech SE

Eli Lilly

The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising growth industry after years of underperformance, but many are top pharma stocks to sell.

3 Pharma Stocks to Sell in February Before They Crash and Burn

The healthcare giant published its fourth-quarter and full-year 2023 results. It beat on both the top and bottom lines for the quarter.

Why Merck Stock Rocketed Nearly 5% Skyward Today

Merck & Co. (MRK) shares traded at an all-time high Thursday after the pharmaceutical company posted a surprisingly positive adjusted profit after sales jumped for its cancer drugs and vaccines.

Merck Stock Hits Record High on Sales of Cancer Drugs, Vaccines

Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance.

Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View

Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript

The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Merck (MRK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Merck & Co Inc (NYSE:MRK) announced surprise fourth-quarter profits of 3 cents per share earlier, as well as revenue of $14.63 billion, both of which easily surpassed analysts' expectations.

Bulls Pick Up Merck Stock After Surprise Quarterly Win

Merck (MRK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $1.62 per share a year ago.

Merck (MRK) Beats Q4 Earnings Estimates

Merck posted a 3-cent a share loss on revenue of $14.6 billion in the fourth quarter. Analysts surveyed by FactSet had expected Merck to report an 11-cent loss on revenue of $14.5 billion.

Merck Stock Jumps as Earnings Beat, Guidance Ahead of Wall Street Expectations

Merck & Co on Thursday reported better-than-expected fourth-quarter results on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine.

Merck posts better-than-expected quarterly results on soaring Keytruda sales

Merck & Co. Inc. on Thursday reported fourth-quarter earnings and sales that beat analysts' expectations, powered by strong growth in cancer and vaccine products.

Merck's fourth-quarter results top estimates, fueled by key cancer drugs and vaccines

Merck reported a surprise profit and beat fourth-quarter sales expectations Thursday in a move that could prod Merck stock within a buy zone.

Merck Reports A Surprise Profit As Keytruda Sales Continue On Their Warpath

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results.

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Verizon

You don't hear as much about the Dow Jones Industrial Average as investors did a few decades ago, as the broad consensus has deemed the S&P 500 a better indicator of market conditions.

IBM, Verizon, Merck stocks lead Dow to new highs

Bristol-Myers

Johnson & Johnson

J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.

Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat

AbbVie

Amgen

Pfizer

Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's first ever price negotiations.

Pharma industry to get US government price cut proposals by Thursday

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Countdown to Merck (MRK) Q4 Earnings: Wall Street Forecasts for Key Metrics

Fiverr

Merck is well on its way to replacing its most important growth driver. Fiverr will continue to benefit from the expanding gig economy.

A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years

Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.

Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Reduced the Risk of Death Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy.

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.

Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices

Healthcare had a mediocre performance in 2023, but it remains a suitable addition to a diversified portfolio due to its defensive characteristics. AbbVie Inc. and Merck & Co., Inc. are attractive healthcare players that also provide steady dividends and potential for growth. AbbVie is navigating the Humira patent cliff and expects to return to earnings growth in 2025, while Merck's Keytruda is driving sales but faces competition with a patent expiration in 2028.

AbbVie And Merck: Defensive Healthcare Plays Providing Income

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Significantly Improved DFS as Adjuvant Therapy in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced UC.

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

News for Merck Stock (MRK)